Myeloid panel analysis
Testing strategy
Analysis of a panel of genes in individuals with a diagnosis or suspected diagnosis of myeloid disorder.
Key indications include:
- Acute myeloid leukaemia
- Myelodysplasia
- Myeloproliferative neoplasm
Analysis is intended to assist with differential diagnoses in these individuals and to identify prognostic markers and potential drug targets. This analysis may reveal molecular markers which can be monitored during the course of a patient's treatment.
This analysis may reveal inherited genetic changes which would have implications for themselves and other family members. This must be communicated with patients when consenting for testing.
NHSE funded test referrals should be in accordance with the National Genomic Test Directory for cancer and meet eligibility criteria:
National Genomic Test Directory (NHS England)
Genes tested
Whole genes analysed are listed below.
Gene / transcript:
- ABL1 / NM_005157, NM_007313
- ANKRD26 / NM_001256053, NM_014915 (inc 5’ UTR)
- ASXL1 / NM_015338
- ATRX / NM_000489
- BCOR / NM_001123383, NM_017745
- BCORL1 / NM_021946
- BRAF / NM_004333
- CBL / NM_005188
- CBLB / NM_170662
- CBLC / NM_012116
- CDKN2A / NM_001195132, NM_000077, NM_058195
- CEBPA / NM_004364
- CHEK2 / NM_001005735, NM_007194
- CSF3R / NM_156039
- CUX1 / NM_001202543, NM_181552
- DDX41 / NM_016222
- DNMT3A / NM_022552, NM_175629
- ETNK / NM_018638.5
- FBXW7 / NM_033632, NM_018315
- FLT3 / NM_004119
- GATA1 / NM_002049
- GATA2 / NM_032638, NM_001145661
- GNAS / NM_000516, NM_001077490
- HRAS / NM_005343, NM_001130442
- IDH2 / NM_002168
- IDH1 / NM_005896, NM_001282386, NM_001282387
- IKZF1 / NM_001220765, NM_006060
- JAK2 / NM_004972
- KDM6A / NM_021140
- KIT / NM_000222
- KRAS / NM_033360
- KMT2A / NM_001197104, NM_005933
- MPL / NM_005373
- NF1 / NM_000267
- NFE2 / NM_001136023, NM_001261461, NM_006163
- NOTCH1 / NM_017617
- NPM1 / NM_002520
- NRAS / NM_002524
- PDGFRA / NM_006206
- PHF6 / NM_032458, NM_001015877
- PPM1D / NM_003620
- PTEN / NM_000314
- PTPN11 / NM_002834
- RAD21 / NM_006265
- RHOA / NM_001664.4, NM_001313941.2
- RUNX1 / NM_001754
- SETBP1 / NM_015559
- SETD2 / NM_014159
- SF3B1 / NM_012433
- SH2B3 / NM_005475
- SMC1A / NM_006306
- SMC3 / NM_005445
- SRSF2 / NM_001195427, NM_003016
- STAG1 / NM_005862
- STAG2 / NM_001042749, NM_006603, NM_001282418
- STAT5B / NM_012448
- TET2 / NM_001127208
- THPO / NM_000460.4, NM_001289998.1, NM_001290028.1
- TP53 / NM_000546, NM_001126112
- U2AF1 / NM_001025203
- UBA1 / NM_003334.4, NM_153280.3
- WT1 / NM_024426
- ZRSR2 / NM_005089
Some hotspot regions are also covered.
Gene Exons / Transcript:
- BRCC3 4,5,6,10 / NM_024332
- CALR 8,9 / NM_004343
- JAK3 11,13,15 / NM_000215
- MYD88 5 / NM_001172567
- SETDB1 11,16 / NM_001145415
- STAT3 20,21 / NM_139276
This panel has been validated to detect variants down to a level of 5 percent.
Target reporting times
21 calendar days for routine referrals
Sample requirements and referral information
Please see referral form for referral information required
Samples required are bone marrow aspirate or peripheral blood in EDTA anticoagulant.
If a liquid sample cannot be obtained then analysis may be possible on DNA extracted from a paraffin embedded sample. Please contact us to discuss.
Reports are available to registered users - NHS networked (N3) computer only
Requesting specialty
Clinical Haematology
Contact details
Myeloid Panel enquiries: oxford.molecularhaem@nhs.net
Price list for non NHSE referrals
Price list for rare disease services (pdf)
Last reviewed:24 May 2022